Dermapharm Holding SE (CHIX:DMPD) Change In Receivables: €0 Mil (TTM As of Mar. 2026)


CHIX:DMPD Dermapharm Holding SE CHIX:DMPD
80 GF Score
Price €46.18
GF Value €39.87
! 10 Warning Signs
View Full Analysis

What is Dermapharm Holding SE Change In Receivables?

Dermapharm Holding SE CHIX:DMPD 80 Change In Receivables is €0 Mil as of Mar. 2026. GuruFocus rates CHIX:DMPD with a GF Score™ of 80/100 and a GF Value™ of €39.87. The stock has 10 warning signs investors should review.

Dermapharm Holding SE's change in receivables for the quarter that ended in Mar. 2026 was €0 Mil. It means Dermapharm Holding SE's Accounts Receivable stayed the same from Dec. 2025 to Mar. 2026 .

Dermapharm Holding SE's change in receivables for the fiscal year that ended in Dec. 2025 was €0 Mil. It means Dermapharm Holding SE's Accounts Receivable stayed the same from Dec. 2024 to Dec. 2025 .

Dermapharm Holding SE's Accounts Receivable for the quarter that ended in Mar. 2026 was €136 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Dermapharm Holding SE's Days Sales Outstanding for the three months ended in Mar. 2026 was 40.53.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Dermapharm Holding SE's liquidation value for the three months ended in Mar. 2026 was €-1,002 Mil.

Dermapharm Holding SE  (CHIX:DMPd) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Dermapharm Holding SE's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=135.822/305.803*91
=40.53

2. In Ben Graham's calculation of liquidation value, Dermapharm Holding SE's accounts receivable are only considered to be worth 75% of book value:

Dermapharm Holding SE's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=253.995-1537.492+0.75 * 135.822+0.5 * 359.66
=-1,002

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dermapharm Holding SE Change In Receivables Related Terms

Dermapharm Holding SE Change In Receivables Historical Data

* Premium members only.

The historical data trend for Dermapharm Holding SE's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dermapharm Holding SE Change In Receivables Chart

Dermapharm Holding SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Dermapharm Holding SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:DMPD
80GF Score
Dermapharm Holding SE CHIX:DMPD
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dermapharm Holding SE Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of €0 Mil mean?
Dermapharm Holding SE (CHIX:DMPD) has a Change In Receivables of €0 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Dermapharm Holding SE and its competitors.
Is Dermapharm Holding SE's Change In Receivables too high?
Dermapharm Holding SE's current Change In Receivables is €0 Mil. Overall, Dermapharm Holding SE has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's Change In Receivables compare to ZTS and UTHR?
Dermapharm Holding SE's Change In Receivables of €0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Drug Manufacturers company?
A good Change In Receivables depends on the Drug Manufacturers industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Dermapharm Holding SE and its competitors. Dermapharm Holding SE's current Change In Receivables is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Dermapharm Holding SE (CHIX:DMPD) has a current Change In Receivables of €0 Mil. The stock's GF Value™ is €39.87, compared to a current price of €46.18 — trading 15.8% above its estimated fair value. The current Change In Receivables is €0 Mil. Dermapharm Holding SE's overall GF Score™ is 80/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Dermapharm Holding SE (CHIX:DMPD), the current Change In Receivables is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dermapharm Holding SE (CHIX:DMPD) Overvalued in 2026?

Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued. The current stock price of €46.18 is trading 15.8% above its estimated GF Value™ of €39.87.

Key valuation signals for CHIX:DMPD:

  • Change In Receivables: €0 Mil
  • GF Value™: €39.87 vs. price of €46.18 (15.8% above fair value)
  • GF Score™: 80/100 with 10 warning signs

No single metric tells the full story. See the CHIX:DMPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dermapharm Holding SE Business Description

Other Exchanges DMPHF:USA0A5J:UKDMP:Germany
Address Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
80GF Score

Get the complete analysis for CHIX:DMPD

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€46.18
Price
€39.87
GF Value